SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The Mullen Army Token originated from a dedicated community of retail investors who faced challenges in the traditional stock market. We united to create a cryptocurrency that embodies our principles and aspirations for a fair financial system.     We provide a platform for retail investors to engage in a transparent and fair financial market. Our efforts include grassroots marketing, community engagement, and educational content to empower our investors.

MullenArmy

The MullenArmy community is actively rallying behind the MULN token on the Solana blockchain, framing it as a high-potential weekend runner despite persistent accusations of being a scam project. While proponents view recent price fluctuations as an accumulation zone for future gains, critics are highlighting its history of extreme volatility and the lack of fundamental utility compared to traditional investments.

Sound Group, Inc. is a global, AI-powered audio company on a mission to help people connect better and live happier. Leveraging its voice AI technologies and deep expertise in audio interaction, Sound Group is building a diverse ecosystem of intelligent audio products that cater to a global user base. By integrating technology, innovative products, and real-world data within a user-centric ecosystem, Sound Group generates a powerful growth flywheel that is driving continuous innovation and accelerating global expansion. The company was founded by Jinnan Lai and Ning Ding in 2010 and is headquartered in Singapore.

Sound Group Inc - ADR

Sound Group Inc

Sound Group Inc is trending as investors digest the announcement of a new special cash dividend and ongoing share buybacks, which many view as a signaling of confidence in the company's profitability and AI-driven growth. The community remains sharply divided, with bulls pointing to high revenue growth and a cash-rich balance sheet as catalysts for further upside, while bears express skepticism regarding the company's reporting standards and the sustainability of its recent rally.

Berkshire Hathaway, Inc. is a holding company, which engages in the provision of property and casualty insurance and reinsurance, utilities and energy, freight rail transportation, finance, manufacturing, and retailing services. It operates through the following segments: Insurance, Burlington Northern Santa Fe, LLC (BNSF), Berkshire Hathaway Energy (BHE), Pilot Travel Centers (PTC), Manufacturing, McLane, and Service and Retailing. The Insurance segment includes the underwriting of GEICO, Berkshire Hathaway Primary Group, and Berkshire Hathaway Reinsurance Group. The BNSF segment involves the operation of railroad systems. The BHE segment focuses on regulated electric and gas utility, power generation and distribution, and real estate brokerage activities. The PTC segment consists of managing travel centers and marketing of wholesale fuel. The Manufacturing segment refers to industrial, consumer and building products, home building, and related financial services. The McLane segment covers the wholesale distribution of groceries and non-food items. The Service and Retailing segment relates to the provision of shared aircraft ownership programs, aviation pilot training, electronic components distribution, retailing businesses, automobile dealerships and trailer, and furniture leasing services. The company was founded by Oliver Chace in 1839 and is headquartered in Omaha, NE.

Berkshire Hathaway Inc. - Ordinary Shares - Class A

Berkshire Hathaway is trending as Warren Buffett prepares to step down as CEO, a move that is driving intense discussion around the firm's massive cash pile, its recent tactical sales of long-term holdings like Apple, and the future strategic direction under incoming CEO Greg Abel. Investors are closely monitoring how the firm will deploy its unprecedented cash reserves, while the broader community debates the potential for a leadership pivot and the transition of the company's legendary capital allocation strategy.

Ethereum is a global, open-source platform for decentralized applications. In other words, it is a decentralized blockchain platform that enables developers to build and deploy smart contracts and applications without central authority control. Unlike Bitcoin, which primarily functions as digital currency, Ethereum operates as a programmable global computer where developers can create any type of decentralized service.   The platform hosts over $14 billion in DeFi applications with hundreds of thousands of active users across financial protocols, NFT marketplaces, and gaming platforms. Its transition to Proof of Stake in September 2022 reduced energy consumption by over 99%, addressing environmental concerns while strengthening network security.  The network operates through thousands of independent validator nodes that process transactions and execute smart contracts on the Ethereum Virtual Machine. Smart contracts are self-executing programs written in Solidity that automatically carry out agreements when conditions are met, eliminating intermediaries like banks or brokers.   Validators stake ETH as collateral to propose and validate blocks, earning rewards for honest participation while facing penalties for malicious behavior. The EIP-1559 upgrade introduced a dynamic base fee mechanism that burns ETH with each transaction, creating deflationary pressure during high network activity when more ETH is burned than issued to validators.  Vitalik Buterin proposed Ethereum in 2013, but seven co-founders helped build it, including Gavin Wood who created Solidity and the EVM technical specification, and Joseph Lubin who founded ConsenSys. The project launched in July 2015 after raising over $18 million through crowdfunding, quickly becoming the largest blockchain developer community. Major milestones include the 2020 Beacon Chain launch, the 2021 London hard fork implementing fee burning, and the 2022 Merge to Proof of Stake.   Ether (ETH) serves multiple functions: paying transaction fees (gas), staking to secure the network and earn 3-5% annual yields, serving as collateral in DeFi protocols, and purchasing NFTs and digital assets. The asset is increasingly adopted by traditional institutions, with publicly traded companies adding ETH to corporate treasuries to generate staking yields while maintaining blockchain exposure, and in 2024, the SEC approved spot Ethereum ETFs, allowing traditional investors to gain exposure through conventional brokerage accounts.  Ethereum's roadmap focuses on dramatically increasing transaction capacity to over 100,000 per second, reducing confirmation times, and enhancing decentralization while maintaining security against future threats like quantum computing.

Ethereum

Ethereum is trending amidst heavy community debate over the impact of geopolitical instability and potential regulatory shifts on its price action. Traders are closely monitoring critical support and resistance levels while weighing the influence of broader institutional accumulation against ongoing market volatility.

GhostwareOS (GHOST) is the Full-Stack Privacy Layer of Solana — a next-generation AI-driven infrastructure for encrypted communication, anonymous identity management, and untraceable transactions. By combining advanced zero-knowledge protocols with autonomous AI routing, GhostwareOS allows users and developers to operate invisibly across Web3. It powers decentralized apps that demand true digital anonymity, scalable privacy, and zero metadata leakage — restoring control to users in an overexposed internet age.

Ghost

Ghost is seeing intense community debate, with bulls highlighting the project's privacy-focused utility within the Solana ecosystem, while skeptics warn of volatility and potential rug-pull risks. The discourse is heavily driven by aggressive social media promotion and speculation surrounding upcoming platform features and ecosystem integrations.

XRP is a decentralized digital asset and the native token of the XRP Ledger, a Layer 1 blockchain designed for high-performance global payments. Its primary value proposition is offering a fast, cost-effective alternative to traditional banking systems by enabling near-instant cross-border settlements that finalize in three to five seconds. By serving as a neutral bridge asset between different fiat currencies, it helps financial institutions lower liquidity costs and eliminates the need for pre-funded accounts.  The network is unique because it utilizes a federated consensus protocol instead of energy-intensive mining or staking. This system achieves deterministic finality through a Unique Node List of trusted validators who must reach an eighty percent agreement threshold to permanently record transactions. This infrastructure supports a sustained throughput of 1,500 transactions per second and includes a built-in decentralized exchange that allows for the automated trading of any tokenized asset without intermediaries.  The project traces its origins back to 2004 with Ryan Fugger before being co-founded in its modern form by Jed McCaleb and Chris Larsen. The company, now known as Ripple, works with major financial institutions as partners and investors to build global payment solutions. To protect the network from spam, a small amount of XRP is burned during every transaction, and the token is further utilized by institutions as collateral to access traditional markets and manage digital asset infrastructure.  Institutional adoption of the asset reached a major milestone in November 2025 when the SEC approved the first wave of spot XRP ETFs. These products, offered by major issuers including Bitwise, Grayscale, 21Shares, Canary Capital, and Franklin Templeton, are now listed on prominent exchanges like the NYSE Arca, Nasdaq, and Cboe BZX. While Ripple remains a key contributor to the ecosystem, the underlying XRP Ledger continues to operate as an open-source and decentralized network.

Ripple

Ripple's (XRP) market conversation is currently driven by developments around its treasury platform's integration with SWIFT and ongoing speculation regarding the Clarity Act, which investors hope will provide regulatory certainty for institutional adoption. The community remains divided, with permabulls focusing on long-term utility and potential supply shocks while bears and skeptics express frustration over stagnant price action and dismiss the symbol as manipulated or failing to deliver on promised growth.

Pump.fun

Pump.fun is actively trending as community members weigh the platform's high-volume meme token activity against ongoing concerns about market volatility and rug pull risks. Discussion is sharply divided between traders highlighting massive earnings and success stories, and skeptics emphasizing the high rate of project failures within the ecosystem.

Fox Corp. engages in providing television production and broadcasting services. It also provides news under the brands FOX News Media, FOX Sports, FOX Entertainment and FOX Television Stations, and Tubi Media Group. It operates through the following segments: Cable Network Programming, Television, and Other and Corporate. The Cable Network Programming segment refers to the production and licensing of news and sports content distributed primarily through traditional cable television systems, direct broadcast satellite operators, and telecommunication companies and online multi-channel video programming distributors. The Television segment focuses on the acquisition, marketing, and distribution of broadcast network programming. The Other and Corporate segment relates to the FOX Studio Lot, Credible Labs Inc, corporate overhead costs, and intracompany eliminations. The company was founded by Keith Rupert Murdoch on May 3, 2018, and is headquartered in New York, NY.

Fox Corporation - Ordinary Shares - Class A

Fox Corporation

Fox Corporation is trending amid intense community discourse regarding its news coverage, editorial direction, and shifting political influence, while investors monitor the company's strategic pivot toward digital growth and sports-streaming integration. Market discussions also reflect high interest in the stock's valuation as analysts weigh its competitive position against long-term cord-cutting pressures and broader media industry volatility.

Navan, Inc. engages in offering a cloud-based technology platform for travelers. Its products include business travel and expense management. The company was founded by Ariel Cohen and Ilan Twig in February 2015 and is headquartered in Palo Alto, CA.

Navan Inc. - Ordinary Shares - Class A

Navan shares are experiencing intense volatility as investors debate the company's long-term profitability and AI-driven growth strategy against significant skepticism regarding its IPO valuation. Community sentiment is deeply divided, with some traders hunting for tactical entry points during price swings while others remain cautious due to ongoing class-action litigation and concerns over financial transparency.

What is Amp?  Amp is described as the new digital collateral token offering instant, verifiable assurances for any kind of value transfer. Using Amp, networks like Flexa can quickly and irreversibly secure transactions for a wide variety of asset-related use cases.  How does Amp work?  Amp claims to offer a straightforward but versatile interface for verifiable collateralization through a system of collateral partitions and collateral managers. Where collateral partitions can be designated to collateralize any account, application, or even transaction, and carry balances which are directly verifiable on the Ethereum blockchain, collateral managers are smart contracts that can lock, release, and redirect collateral in these partitions as needed in order to support value transfer activities. Amp supports a wide variety of use cases for collateralization, and also introduces the concept of predefined partition strategies, which can enable special capabilities such as collateral models through which tokens can be staked without ever leaving their original address.

AMP Token

AMP is trending as investors react to volatility and shifting community sentiment regarding the upcoming Clarity Act, with many debating whether the token's real-world utility in payment infrastructure justifies its long-term investment case. The discourse is heavily polarized, featuring both optimistic supporters who are focused on institutional adoption and regulatory clarity, and vocal critics who are frustrated by prolonged price stagnation and a lack of direct updates from the development team.

statis crypto Watchlist

Bitcoin

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$ALT BIC vs $AKERO, $ETNB , $MTSR , $MDGL , $VKTX - AI read and NITs will be the standard and $ALT is leading. 
 
KOLs are not wrong when they say biopsy can miss or misclassify disease.  
1️⃣ Sampling error (the biggest problem) 
 
A biopsy samples ~1/50,000 of the liver 
 
Fibrosis and inflammation are heterogeneous 
 
One core can show F2, another F3 or F1 in the same patient 
 
Studies show: 
 
20–30% discordance in fibrosis staging between two biopsy samples from the same liver 
 
Inter-reader variability even among expert pathologists 
 
👉 This means biopsy can both overestimate and underestimate response. 
 
2️⃣ Noise overwhelms signal in short trials 
 
Fibrosis remodeling is slow 
 
24–52 weeks is often borderline too short to see clean stage shifts 
 
A true biological improvement may not cross the ≥1-stage threshold because of: 
 
Baseline misclassification 
 
Borderline staging 
 
Patchy regression 
 
This is why KOLs often say: 
 
“The drug worked, but the biopsy couldn’t see it.”

Patrick R.

Lynxtail

Charlie gomes

Peter Quick

Bio Control

Chop1182

Rajesh

Jamee's Man

StockTwits Web

Altimmune Inc

89bio Inc

Metsera Inc

Madrigal Pharmaceuticals Inc

Viking Therapeutics Inc

 - AI read and NITs will be the standard and 

 is leading. 
 
KOLs are not wrong when they say biopsy can miss or misclassify disease.  
1️⃣ Sampling error (the biggest problem) 
 
A biopsy samples ~1/50,000 of the liver 
 
Fibrosis and inflammation are heterogeneous 
 
One core can show F2, another F3 or F1 in the same patient 
 
Studies show: 
 
20–30% discordance in fibrosis staging between two biopsy samples from the same liver 
 
Inter-reader variability even among expert pathologists 
 
👉 This means biopsy can both overestimate and underestimate response. 
 
2️⃣ Noise overwhelms signal in short trials 
 
Fibrosis remodeling is slow 
 
24–52 weeks is often borderline too short to see clean stage shifts 
 
A true biological improvement may not cross the ≥1-stage threshold because of: 
 
Baseline misclassification 
 
Borderline staging 
 
Patchy regression 
 
This is why KOLs often say: 
 
“The drug worked, but the biopsy couldn’t see it.”

Moderna Inc

Pfizer Inc

Arbutus Biopharma Corp

BioNTech SE - ADR

The Patient One

2 -  
3️⃣ Biopsy is binary, biology is continuous 
 
Biopsy forces: 
 
Continuous biology → discrete buckets (F2 vs F3) 
 
Which amplifies noise near cutoffs 
 
NITs (ELF, LSM, cT1): 
 
Capture continuous change 
 
Track trajectory 
 
Often detect improvement earlier than biopsy 
 
This is exactly why KOLs increasingly trust NIT trends clinically.

3- 
So why does biopsy still matter if KOLs distrust it? 
 
Here’s the uncomfortable truth: 
 
👉 Regulators don’t require biopsy because it’s perfect — they require it because it’s the least imperfect common standard we’ve historically had. 
 
Biopsy persists because: 
 
It is direct tissue evidence 
 
It has decades of outcome correlation 
 
It allows binary regulatory decisions 
 
There is no single NIT yet validated to replace it globally 
 
Regulation is conservative by design. It lags science. 
 
Why KOLs and regulators are talking past each other 
 
KOLs are asking: 
 
“Which tool best reflects true disease biology?” 
 
Regulators are asking: 
 
“Which tool can we defend in court, across regions, consistently, today?” 
 
Those are different questions. 
 
This is why the EMA is moving faster than the FDA 
 
European regulators are increasingly saying: 
 
“If multiple NITs move together” 
 
“If changes are large and durable” 
 
“If biology is coherent”

4- 
Then: 
 
Biopsy may not be required upfront 
 
Or can be deferred/post-approval 
 
KOL influence is absolutely shaping this shift. 
 
But we’re in a transition period, not the end state. 
 
Why this actually strengthens Altimmune’s position (important) 
 
Altimmune’s 48-week data does something biopsy often fails to do: 
 
Shows consistent improvement across multiple orthogonal NITs 
 
Shows durability 
 
Shows dose response 
 
Shows metabolic + liver coherence 
 
That is exactly the pattern KOLs say: 
 
“This is real biology, not noise.” 
 
So scientifically: 
 
ALT’s data is very strong 
 
Regulatorily: 
 
The system hasn’t fully caught up yet

5- 
Markets don’t use biopsy because it’s right — they use it because: 
Deals 
Approvals 
So histology remains the financial clearing mechanism, even as its scientific authority erodes. 
That’s the paradox you’re sensing — and you’re correct to question it. 
Where this is heading (and KOLs agree on this) 
The consensus direction is: 
Short term (now): 
Biopsy + NITs 
Medium term: 
Composite NIT endpoints accepted (especially EMA) 
Long term: 
Biopsy largely phased out except in edge cases 
We are mid-transition, not post-transition. 
Bottom line (this is the clean resolution) 
You are correct: 
Biopsy can miss real effects 
Biopsy can be wrong 
KOLs increasingly trust NITs more 
But: 
Regulation and markets still price biopsy 
Until NITs are formally elevated to surrogate status globally 
So when histology enters valuation discussions, it’s not because it’s scientifically superior — 
it’s because it’s institutionally entrenched. 
 
Altimmune’s data aligns with where medicine is going, not where regulation fully is yet.